Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease
Open Access
- 20 June 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (25), 5098-5103
- https://doi.org/10.1182/blood-2012-10-464198
Abstract
Key Points. Incidence of sclerotic GVHD is 20% by 3 years after initial systemic treatment for chronic GVHD.The use of mobilized blood cell graft and total bodThis publication has 29 references indexed in Scilit:
- Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of diseaseBlood, 2011
- Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantationBlood, 2011
- Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysisBlood, 2011
- Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteriaBlood, 2011
- Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseasesBest Practice & Research Clinical Haematology, 2010
- Evaluation of NIH consensus criteria for classification of late acute and chronic GVHDBlood, 2009
- Cutaneous Chronic Graft-Versus-Host Disease Does Not Have the Abnormal Endothelial Phenotype or Vascular Rarefaction Characteristic of Systemic SclerosisPLOS ONE, 2009
- An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimensBlood, 2006
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- GRAFT-VERSUS-HOST DISEASE LIMITED TO AREA OF IRRADIATED SKINThe Lancet, 1980